Ionis Pharmaceuticals Inc (IONS) Stock AnalysisIONSStock AnalysisIonis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ionis Pharmaceuticals is a good buy right now due to its recent FDA approval of Tryngolza, which is expected to significantly boost future revenues. The current price of $61.05 is below the analyst price target range of $76 to $115, indicating potential upside. Additionally, the stock has shown a 17.93% increase over the last 20 days, reflecting positive momentum. However, the main risk is the company's negative net income, which was -114646000 USD in Q2 2026, indicating ongoing financial challenges.

15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.